39. Whiteside TL. Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy. Clin
Diagn Lab Immunol. 2000;7(3):327–32.
40. Gjertsen MK, Buanes T, Rosseland AR, et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating
factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer. 2001;92(3):441–50.
41. Whiteside TL, Gooding W. Immune monitoring of human gene therapy trials: potential application to leukemia and lymphoma.
Blood Cells Mol Dis. 2003;31(1):63–71.
42. Prussin C, Metcalfe DD. Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine
antibodies. J Immunol Methods. 1995;188(1):117–28.
43. Whiteside TL. ELISPOT assays. In: Nagorsen D, Marincola, FM, ed. Analyzing T Cell Responses. New York: Springer Publishers;
2005:143–57.
44. Hoffmann TK, Donnenberg VS, Friebe-Hoffmann U, et al. Competition of peptide-MHC class I tetrameric complexes with anti-CD3
provides evidence for specificity of peptide binding to the TCR complex. Cytometry. 2000;41(4):321–28.
45. Whiteside TL, Zhao Y, Tsukishiro T, Elder EM, Gooding W, Baar J. Enzyme-linked immunospot, cytokine flow cytometry, and
tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin
Cancer Res. 2003;9(2):641–49.
46. Markovic SN, Nevala WK, Uhl CB, Celis E, McKean DJ. A reproducible method for the enumeration of functional (cytokine
producing) versus non-functional peptide-specific cytotoxic T lymphocytes in human peripheral blood. Clin Exp Immunol. 2006;145(3):438–47.
47. Asai T, Storkus WJ, Whiteside TL. Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients
receiving antitumor vaccines. Clin Diagn Lab Immunol. 2000;7(2):145–54.
48. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274(5284):94–6.
49. Albers AE, Ferris RL, Kim GG, Chikamatsu K, DeLeo AB, Whiteside TL. Immune responses to p53 in patients with cancer: enrichment
in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol Immunother. 2005;54(11):1072–81.
50. Speiser DE, Pittet MJ, Guillaume P, et al. Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment
of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring. J Immunother. 2004;27(4):298–308.
51. Drake DR, 3rd, Ream RM, Lawrence CW, Braciale TJ. Transient loss of MHC class I tetramer binding after CD8+ T cell activation
reflects altered T cell effector function. J Immunol. 2005;175(3):1507–15.
52. Miltenyi S, Muller W, Weichel W, Radbruch A. High gradient magnetic cell separation with MACS. Cytometry. 1990;11(2):231–38.
53. Okamoto Y, Nishida M. Dual-color ELISPOT assay for analyzing cytokine balance. Methods Mol Biol. 2005;302:263–72.
54. Osada T, Clay TM, Woo CY, Morse MA, Lyerly K. Dendritic cell-based immunotherapy. Int Rev Immunol. 2007;25(5):377–413.
55. De Vries IJ, Berensen MR, Lestrehuis WJ, et al. Immunomonitoring for tumor-specific T cells in delayed-type hypersensitivity
skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol. 2005;23(24):5779–87.
56. Wierecky J, Muller MR, Wirths S, et al. Immunologic and clinical responses after vaccination with peptide-pulsed dendritic
cells in metastatic renal cancer patients. Cancer Res. 2006;66(11):5910–18.
|
